Laurus Labs. Source: Company Data

Transcription

1 Strong R&D capabilities, coupled with high debt and WC December 06, 2016 Surajit Pal Rating Price Band Subscribe Rs IPO Fact Sheet Opening Date Dec 06, 2016 Closing Date Dec 08, 2016 BRLMs Kotak Mahindra Capital, Citigroup Global Markets India, Jefferies India, SBI Capital Markets Issue Size Rs13,305.1m Issue Details Pre issue equity (m shares) 98.7 Fresh issue of shares (m shares)* 7.04 Offer for sale 24.1 Post issue equity (m shares)* Post issue Market Cap (Rs bn)* Share Holding (%) Pre IssuePost Issue* Promoters Public & Others *Equity issuance calculated on higher price band Objects of the Issue The IPO is largely an exit route for existing investors and the company will raise Rs3000m by issuing new shares. Out of this, Rs2250m will be used for repayment / pre payment of certain loans availed by the company and for general corporate purposes Laurus Labs Limited is a leading R&D driven pharmaceutical company with a niche position into development of generic APIs in therapeutic areas of Anti retroviral (ARV) and Hepatitis C (Hep C). The company operates in four business lines, manufacturing of generic APIs, FDF generics, Synthesis and Ingredients. The company has launched 59 products since its inception in The company has an enviable customer base of 9 out of 10 generic global pharmaceutical majors including Aurobindo Pharma, Strides Shasun, Cipla, Mylan, NATCO Pharma and Aspen Pharmacare Limited. The top 5 customers have contributed 68% of total revenues in FY16, which have been reduced to 59% in H1FY17. The company s total revenues and restated PAT on a standalone basis grew at CAGR of 41% and 61% in FY12 16 respectively. The company is led by qualified and experienced promoters with managerial experience in Matrix and Ranbaxy and has an established track record of delivering growth. The company s shareholders include marquee investors such as Bluewater (Warbur Pincus Group), FIL Capital (earlier known as Fidelity growth partners) and Aptuit. With strong capex to develop plant infrastructure since inception, Laurus have high debt and we expect the company to continue current capex plan of Rs9bn in FY17E 19E. Laurus also plans to foray into FDFs (formulations) in US market including expectation of exclusivities in two products with potential launch in FY19E 20E. The company targets to file 10 ANDAs each in FY17E 19E. With major number of ARV drugs are going off patent in FY17E 21E, we expect the company to receive strong order flow from key ARV players such as Aurobindo, Natco Pharma, Strides Shasun and Cipla, who are already its existing clients for the production of Efavirenz in global market. With IPO price band of INR per share, Laurus Lab is valued at PER of 31.6x 31.8x of FY16 earnings. The company s FY16 EPS of Rs20.9 on pre money valuations and Rs13.5 at Post money valuation. Of the IPO size of Rs13.3bn. Rs3bn is fresh issue and the remaining 24.1m shares are OFS. While we do not expect any immediate listing gains, we believe the IPO of Laurus Lab is deep in value given its foray into FDFs, ARVs and oncology drugs in US. We recommend Subscribe with a longterm strategy. Key financials FY14 FY15 FY16 Revenues (Rs m) 11,657 13,379 18,172 Growth 14.7% 35.8% EBITDA (Rs m) 2,177 2,343 3,798 PAT (Rs m) ,327 EPS (Rs)* Profitability & Valuation FY14 FY15 FY16 EBITDA margin 18.7% 17.5% 20.9% RoNW 27.1% 9.5% 15.6% FCF (1,879) (4,478) (1,437) Working Capital Days IPO Note Prabhudas Lilladher Pvt. Ltd. and/or its associates (the 'Firm') does and/or seeks to do business with companies covered in its research reports. As a result investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of the report. Investors should consider this report as only a single factor in making their investment decision. Please refer to important disclosures and disclaimers at the end of the report

2 Exhibit 1: Issue Details Company Laurus Labs Limited Laurus Labs Limited is a leading research and development (R&D) driven Pharmaceutical company in India, with a leadership position in Profile generic active pharmaceutical ingredients (APIs) for select, high growth therapeutic areas of anti retrovirals (ARVs) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas. Offer Period Opens On : Tuesday, December 06, 2016 Closes On : Thursday, December 08, 2016 Price Band Rs. 426 Rs. 428 Bid Lot Issue Size 35 Equity Shares & in multiple thereafter Rs m Rs m. QIB NIB Retail 50% of the Issue 15% of the Issue 35% of the Issue Mode of Payment ASBA Mandatory (No Cheques will be accepted) Registrar Lead Manager Karvy Computershare Private Limited Kotak Mahindra Capital, Citigroup Global Markets, Jefferies India & SBI Capital Markets Listing NSE and BSE Company Background and Business: Laurus Labs Limited ( Laurus Labs ) was incorporated on September 19, 2005 at Hyderabad, Andhra Pradesh as a Private Limited Company. The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited. The name of the company was changed to Aptuit Laurus Limited consequent to the strategic partnership entered into by the company with Aptuit Singapore. Thereafter the company was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited. Subsequently the name of the company was changed to Laurus Labs Private Limited consequent to the proposed dilution of the shareholding of Aptuit Singapore in the company. The company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited The company is a leading R&D driven pharmaceutical company in India, with a leadership position in generic APIs in select, high growth therapeutic areas of antiretrovirals (ARVs) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas. They are leading suppliers of APIs in the ARV segment to MNC pharma formulations companies as a result of their strategic and early investments in R&D. During FY16, the company has sold its APIs accross 32 countries December 06,

3 Laurus Labs operates in four business segments which are Generics APIs, Generics FDFs, Synthesis and Ingredients. Exhibit 2: Business Segments Revenue Revenue (Rs m) Business Lines Description FY2014 FY2015 FY2016 Sep' 2016 Development, manufacture and sale Generics APIs of APIs 10,907 21,534 16,517 8,546 and Advanced Intermediates. Development and manufacture of Generics FDFs Oral Solid Formulations Contract development & Synthesis manufacturing services for global pharma companies Ingredients Manufacture and sale of specialty ingredients for use in the Nutraceutical & Cosmeceutical sectors The company has four manufacturing facilities and is in the process of setting up another two. Of these, two are for the manufacture of APIs and the third is for the manufacture of APIs and FDFs, both and one kilo lab facility at Hyderabad. The two new facilities are for the manufacture of APIs Promoter s Background: Amal Ganguli Non Executive, Chairman and Independent Director He has been a Director of the company since September 7, He has over 40 years of experience in the field of international tax and planning, cross border investments, corporate mergers and re organizations, financial evaluation of projects, management, operational and statutory audit and consulting projects funded by international funding agencies Dr. Satyanarayana Chava Executive, Wholetime Director; Chief Executive Officer He has been a Director of the company since January 21, He has been determined as inventor in 103 patents granted or patent applications filed across the world Dr. Raju Srihari Kalidindi Executive, Wholetime Director He has over 23 years of experience in research and pharmaceutical industry, including more than 10 years at Hospira Australia Pty Ltd in Australia. His areas of expertise include research and development, operations, sourcing and business development. Dr. Kalidindi has been determined as inventor in 11 patents granted or patent applications filed across the world December 06,

4 Ravikumar V V Executive, Wholetime Director; Chief Financial Officer He has been a Director of the company since November 30, 2006 and is in charge of finance, information systems and human resources function of the Company. He has over 25 years of experience in the field of Finance Chandrakanth Chereddi Executive and Wholetime Director He has been associated with the company since February 10, 2012 and is involved in strategy and operation of the company. He has over 8 years of experience in the field of Project Management Among the Promoters, Dr. Satyanarayana Chava, Dr. Raju Srihari Kalidindi and Ravi Kumar V V have extensive experience in the pharmaceutical industry Operations: Laurus Labs has a concentrated client base. Top 5 customers accounted for 67.8% of its consolidated revenues in FY2016. Major customers include Aurobindo Pharma, Cipla, NATCO, Strides Shasun, Mylan and Aspen Pharmacare Limited. The company also has varied contracts including ones with Dr. Reddy s Laboratories and NATCO Pharma R&D Centre: Laurus Labs has set up their 1st dedicated R&D center in Hyderabad, Telangana in Initially they focused on research in the Oncology and ARV API areas and after making progress in R&D they commissioned their 1st API manufacturing facility in The kilo lab at their R&D center at Hyderabad has received approvals from the United States Food and Drug Administration ( US FDA ), Pharmaceuticals and Medical Devices Agency ( PMDA ) of Japan and the Korea Food and Drug Administration ( KFDA ). They have also set up a R&D center in Greater Boston, United States in 2015 As of September 30, 2016, Laurus Labs has employed 605 scientists at their R&D center in Hyderabad and 12 scientists at their R&D centre in Greater Boston, which constituted 24.4% of their total employee strength. The Company spent Rs.522.8m (5.6%), Rs.906.5m (5.1%), Rs.586.5m (4.3%) and Rs.424m (3.6%) towards their R&D activities during the six months ended September 30, 2016 and the financial years 2016, 2015 and 2014 respectively. They are currently in the process of expanding their R&D center in Hyderabad and setting up another R&D center in Visakhapatnam. The R&D expenses have been consistently on the rise. December 06,

5 Generics API Business: The Generics API business comprises of the development, manufacture and sale of APIs and advanced intermediates in the ARV, Hepatitis C, Oncology, Cardio Vascular, Anti diabetic, Anti asthmatic, Gastroenterology and Ophthalmic therapeutic areas For the 6 months ended September 30, 2016 and the financial years 2016, 2015 and 2014, the revenue from the Generics API business was Rs.8.54bn, Rs.16.51bn, Rs.12.53bn and Rs.10.90bns or 90.7%, 92.2%, 92.1% and 93.3% of the total revenues, respectively. Three core areas in this segment for the company are: ARV Therapeutic Area Hepatitis C Therapeutic Area Oncology Therapeutic Area Generics FDF Business: Company s Generics FDF business comprises the development and manufacture of oral solid formulations. Company s R&D capabilities and API production capabilities can be a key to the growth of their FDF business and allow them to capture significant operating efficiencies by housing both API and FDF facilities in the same location. As of September 30, 2016, the company has invested Rs2.96bn towards growing their FDF business, of which Rs2.09bn was invested to set up an FDF manufacturing facility. This facility has a current capacity of 1bn tablets per year and has civil infrastructure in place, which could increase their manufacturing capacity at this facility to 5bn tablets per year, after incurring additional investments. They intend to file their own registrations in the US and European markets and also market them, and also collaborate with generic companies having front end presence for the sale and marketing of their FDF products. They have recently filed 1 dossier with WHO and an ANDA application in the United States. They have several formulation dossiers under development for the US, Europe and other emerging markets and intend to selectively pursue Paragraph IV filing opportunities in the US. Synthesis Business: As part of the Synthesis business, Laurus Labs perform contract development and manufacturing services for global pharmaceutical companies from pre clinical supplies to commercial scale manufacturing. December 06,

6 During the financial year 2015, they established their wholly owned subsidiary in the United States, Laurus Synthesis Inc., to directly offer their services to US clients. They also established an R&D center in Greater Boston, Massachusetts, in As of September 30, 2016, this R&D center has a team of 12 scientists and 4 sales personnel, who are focused on strengthening their synthesis business. The services offered under the Synthesis business include: Alternate route development, Process development, Process optimization and validation, Scale up of clinical phase new chemical entities, and Commercial manufacturing Ingredients Business: Company s Ingredients business comprises the manufacture and sale of specialty ingredients for use in nutraceutical, dietary supplements and cosmeceutical products. The Ingredients business allows them to leverage their existing R&D, process chemistry competence and manufacturing capabilities. The current portfolios of products are used to make anti oxidants, skin brighteners and UV protection agents. They are also developing capabilities for botanical extraction and purification, to capture the growing shift in the market to natural ingredients. The key products of the Ingredients business include: Pterostilbine (anti oxidant), Resveratrol (anti oxidant), Curcumin (anti oxidant, anti inflammatory), Pterostilbine caffeine co crystals (caffeine bioavailability enhancer), Hexyl Resorcinol (skin brightening), and Bakuchiol (skin brightening) Reasons for IPO: The IPO is largely an exit route for existing investors and the company will raise Rs3000m by issuing new shares. Out of this, Rs2250m will be used for repayment / pre payment of certain loans availed by the company and for general corporate purposes December 06,

7 Financials Exhibit 3: Consolidated Profit & Loss Statement Particulars H1FY17 Income Revenue from operations (Gross) 11,657 13,379 18,172 9,453 Less: Excise duty Revenue from operations (Net) 11,597 13,266 17,838 9,296 Other income Total revenue ( A ) 11,685 13,607 17,914 9,418 Expenses Cost of materials consumed 7,883 9,066 10,183 5,240 Purchase of traded goods Increase in inventories of finished Other manufacturing expenses 777 1,232 1, Employee benefits expenses 1,041 1,328 1,897 1,177 Operating and selling expenses Total expenses ( B ) 9,509 11,264 14,116 7,330 EBITDA(A B) 2,177 2,343 3,798 2,088 Depreciation and amortisation Finance expenses 639 1,062 1, Restated profit before tax 1, ,676 1,023 Tax expense Current tax Minimum alternate tax credit Deferred tax charge/(credit) Total tax expense /(credit) Share of results of associate Restated profit for the year , December 06,

8 Exhibit 4: Consolidated Balance Sheet Particulars H1FY17 Equity and liabilities Shareholders' funds Share capital Reserves and surplus 2,806 6,400 7,694 8,302 Non current liabilities Long term borrowings 1,882 3,037 4,606 2,829 Deferred tax liabilities (net) Other long term liabilities Long term provisions Current liabilities Short term borrowings 3,122 4,316 4,814 5,758 Trade payables 2,275 2,308 2,493 3,083 Other current liabilities 1,643 1,333 1,445 3,537 Short term provisions Total 12,732 18,883 23,030 25,805 Assets Fixed assets Tangible assets 4,943 7,949 10,793 10,524 Intangible assets Capital work in progress 1,161 1, ,164 Goodwill on consolidation 3 Non current investments Long term loans and advances ,286 1,519 Other non current assets Current assets Inventories 3,281 4,755 4,871 5,214 Trade receivables 1,949 2,851 4,449 5,332 Cash and bank balances Short term loans and advances Other current assets Total 12,732 18,883 23,030 25,805 Exhibit 5: Cash Flow (Rs m) Particulars H1FY17 Net Cash Flow from Operating activities 1, ,933 1,189 Net Cash Flow Used In Investing activities 3,118 3,970 3,252 1,758 Net Cash Flow From Financing activities 2,030 4,861 1, Net Cash Generated Capex 3,091 3,831 3,370 1,768 FCF December 06,

9 Prabhudas Lilladher Pvt. Ltd. 3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai , India Tel: (91 22) Fax: (91 22) Rating Distribution of Research Coverage PL s Recommendation Nomenclature % of Total Coverage 70% 60% 50% 40% 30% 20% 10% 0% 60.7% 25.6% 13.7% 0.0% BUY Accumulate Reduce Sell BUY : Over 15% Outperformance to Sensex over 12 months Accumulate : Outperformance to Sensex over 12 months Reduce : Underperformance to Sensex over 12 months Sell : Over 15% underperformance to Sensex over 12 months Trading Buy : Over 10% absolute upside in 1 month Trading Sell : Over 10% absolute decline in 1 month Not Rated (NR) : No specific call on the stock Under Review (UR) : Rating likely to change shortly DISCLAIMER/DISCLOSURES ANALYST CERTIFICATION We/I, Mr. Surajit Pal (PGDBA, CFA, M.Com), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Terms & conditions and other disclosures: Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as PL ) is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication. PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document. PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities. PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company. PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report. PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report. PL or its associates might have received compensation from the subject company in the past twelve months. PL or its associates might have managed or co managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months. PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report. PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report. It is confirmed that Mr. Surajit Pal (PGDBA, CFA, M.Com), Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all o the foregoing, among other things, may give rise to real or potential conflicts of interest. PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. DISCLAIMER/DISCLOSURES (FOR US CLIENTS) ANALYST CERTIFICATION The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report Terms & conditions and other disclosures: This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a 6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a 6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer. December 06,